As growing research on MDMA-assisted therapy to treat PTSD reveals exciting potential, a new study focuses on its cost-effectiveness. The findings show that not only can the treatment improve and extend lives, it can also reduce healthcare costs. This information could help increase willingness of third-party payers to cover costs and improve access to treatment.